Bone–Cartilage Interface Restoration in Osteoarthritis: Mechanisms, Evidence, and Clinical Advances

Abstract

Osteoarthritis (OA) represents a leading cause of disability worldwide, characterized by progressive degeneration of joint tissues, notably the bone–cartilage interface. Restoration of this critical interface has emerged as a focal point in contemporary OA management, as its dysfunction underpins pain, loss of function, and disease progression. This review synthesizes current scientific knowledge on the pathophysiology, risk factors, clinical presentation, and diagnostic approaches related to bone–cartilage interface disruption in OA. It further discusses established and emerging therapeutic strategies, including molecular, cellular, and tissue engineering interventions, while highlighting the latest guideline recommendations and future research directions for optimal patient outcomes.

Introduction

Osteoarthritis is a complex, multifactorial joint disorder predominantly affecting the elderly. Central to OA pathogenesis is the deterioration of the bone–cartilage interface, a specialized region essential for joint integrity, shock absorption, and biomechanical function. Disruption at this juncture not only precipitates cartilage erosion but also subchondral bone remodeling, perpetuating a vicious cycle of joint degeneration. Understanding the intricate biology of the bone–cartilage interface is pivotal for developing targeted interventions that transcend symptomatic relief and aim for structural restoration.

Epidemiology / Disease Burden

Globally, OA affects over 300 million individuals, with the knee, hip, and hand joints most commonly involved. The increasing prevalence correlates with aging populations, obesity, and rising life expectancy. OA imposes significant socioeconomic burdens, accounting for substantial healthcare utilization, loss of productivity, and reduced quality of life. The bone–cartilage interface is increasingly recognized as a therapeutic target, as its degeneration closely aligns with radiographic progression and symptom severity, thus underscoring the imperative for restorative strategies.

Pathophysiology

The bone–cartilage interface, comprising the articular cartilage, calcified cartilage, and subchondral bone, ensures biomechanical stability and load transmission. In OA, mechanical overload, metabolic dysregulation, and inflammatory mediators disrupt this interface. Chondrocyte apoptosis, matrix metalloproteinase activation, and subchondral bone sclerosis lead to fissures, microcracks, and vascular invasion, eroding the tidemark and promoting cartilage loss. Aberrant bone remodeling and osteophyte formation further perpetuate interface breakdown, amplifying nociceptive signaling and functional impairment.

Risk Factors

Major risk factors for OA include age, female sex, obesity, joint trauma, genetic predisposition, and metabolic comorbidities such as diabetes and dyslipidemia. Biomechanical factors, including malalignment and abnormal joint loading, accelerate bone–cartilage interface degeneration. Systemic inflammation, hormonal changes, and impaired subchondral bone perfusion contribute to the pathophysiological cascade, highlighting the multifaceted nature of risk and the need for personalized prevention and intervention strategies.

Clinical Features

OA typically presents insidiously with joint pain, stiffness, crepitus, limited range of motion, and, in advanced cases, deformity. Bone–cartilage interface disruption is often associated with deep, activity-related pain due to subchondral bone exposure and microfracture. Effusions, bony enlargement, and functional limitations frequently ensue, impairing daily activities and mobility. Early recognition of interface-related symptoms is critical for timely diagnosis and intervention, potentially slowing disease progression.

Diagnosis

Diagnosis of OA relies on clinical assessment corroborated by imaging. Conventional radiography reveals joint space narrowing, subchondral sclerosis, and osteophyte formation, while magnetic resonance imaging (MRI) offers superior visualization of cartilage integrity, subchondral bone changes, and bone marrow lesions at the interface. Advanced modalities, such as quantitative MRI and high-resolution computed tomography (CT), provide detailed assessment of the bone–cartilage interface microarchitecture, facilitating early detection and monitoring of therapeutic response.

Treatment & Management

Current management of OA targets symptom alleviation, functional preservation, and structural modification. Non-pharmacologic interventions include weight management, physical therapy, and biomechanical correction. Pharmacologic options encompass NSAIDs, intra-articular corticosteroids, and viscosupplementation. Recent guidelines advocate for a personalized approach, integrating patient preferences, comorbidities, and disease severity. For bone–cartilage interface restoration, surgical techniques such as microfracture, osteochondral autograft/allograft transplantation, and autologous chondrocyte implantation are employed, with variable efficacy and durability.

Recent Advances / Emerging Therapies

Innovations in molecular biology and regenerative medicine have catalyzed the development of novel therapies targeting the bone–cartilage interface. Mesenchymal stem cell (MSC) therapy, tissue-engineered scaffolds, and gene editing approaches aim to regenerate both cartilage and subchondral bone, restoring interface architecture and function. Biologics modulating Wnt/β-catenin, BMP, and TGF-β signaling pathways show promise in preclinical and early clinical trials. 3D bioprinting and nanomaterial-based constructs offer precise spatial organization for interface integration, heralding a new era in OA therapeutics.

Guideline Recommendations

Recent international guidelines from organizations such as OARSI and EULAR emphasize the importance of early, multimodal intervention in OA. While pharmacologic and non-pharmacologic measures remain foundational, there is increasing endorsement of biologic and regenerative therapies for patients with refractory symptoms and focal bone–cartilage defects. Shared decision-making, patient education, and ongoing monitoring are integral to optimizing outcomes and minimizing adverse events. Continued research into interface-specific biomarkers and imaging modalities is encouraged to refine patient selection and therapeutic targeting.

Conclusion

Restoration of the bone–cartilage interface represents a paradigm shift in osteoarthritis management, moving from palliative care to structural repair and disease modification. Advances in understanding the molecular and biomechanical underpinnings of interface degeneration have spurred the development of innovative diagnostics and therapeutics. While challenges remain in translating experimental successes to consistent clinical benefit, ongoing research and multidisciplinary collaboration promise to enhance the prognosis and quality of life for individuals afflicted by OA. Clinicians are urged to remain abreast of emerging evidence, integrate guideline-based practices, and adopt a holistic, patient-centered approach to bone–cartilage interface restoration.